Literature DB >> 10958223

Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.

M Schöniger-Hekele1, C Müller, M Kutilek, C Oesterreicher, P Ferenci, A Gangl.   

Abstract

BACKGROUND AND AIMS: The aetiology of chronic liver disease leading to hepatocellular carcinoma (HCC) and the clinical characteristics at the time of presentation vary considerably among different parts of the world and over time. The number of patients seen at our institution has increased as compared to a period 20 years earlier. We investigated baseline characteristics of patients with hepatocellular carcinoma such as cirrhosis, hepatitis virus markers, age at presentation and stage of the tumour in an area with low prevalence of viral hepatitis.
METHODS: All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study, and 19 different clinical characteristics were studied.
RESULTS: The median age at detection of HCC was 63.3 years, and alcoholic liver disease (35.1%) and hepatitis C virus (HCV) infection (36.7%) were the most frequent underlying diseases. Both chronic alcoholism and HCV infection as risk factors were present in 6.9% of the patients. Liver cirrhosis was present in 86.5%. At the time of diagnosis, 43.5% had multi-nodular tumours. Of the remaining patients with a single nodule, only 10% had HCC < or =2 cm. Most of our patients presented at a late stage of the disease (TNM stage 3 29.4%, TNM stage 4 69.7%; Okuda stage 2 65.7%, Okuda stage 3 18.0%). Due to the late stage of the disease at the time of presentation, 145 patients (59.2%) received palliative care only, 24 (9.8%) underwent liver resection, 38 (15.5%) liver transplantation and 38 (15.5%) chemotherapy.
CONCLUSIONS: In this large single-centre series of HCC, the dominant contribution of HCV infection and chronic alcohol abuse as the underlying aetiology is documented. Diagnosis is usually made very late as reflected in the high proportion of patients in TNM stages 3 and 4 or Okuda stages 2 and 3. This resulted in a high percentage of patients who received palliative care only and very few who were eligible for treatment modalities with curative potential such as resection and liver transplantation.

Entities:  

Mesh:

Year:  2000        PMID: 10958223     DOI: 10.1097/00042737-200012080-00015

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  18 in total

1.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Authors:  Pierre Nahon; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Claude Trinchet; Nathalie Ganne-Carrié
Journal:  Hepat Oncol       Date:  2015-01-12

Review 3.  Treatment of alcoholic liver disease.

Authors:  Ina Bergheim; Craig J McClain; Gavin E Arteel
Journal:  Dig Dis       Date:  2005       Impact factor: 2.404

4.  Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

Authors:  Florian Hucke; Wolfgang Sieghart; Maximilian Schöniger-Hekele; Markus Peck-Radosavljevic; Christian Müller
Journal:  Wien Klin Wochenschr       Date:  2011-07-29       Impact factor: 1.704

Review 5.  Neutrophil Extracellular Traps and Liver Disease.

Authors:  Moira B Hilscher; Vijay H Shah
Journal:  Semin Liver Dis       Date:  2019-11-14       Impact factor: 6.115

Review 6.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

7.  Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Cheng-Yuan Hsia; Gar-Yang Chau; Wing-Yiu Lui; Yi-Hsiang Huang; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

8.  Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma.

Authors:  Gregory C Connolly; Rui Chen; Ollivier Hyrien; Parvez Mantry; Adel Bozorgzadeh; Peter Abt; Alok A Khorana
Journal:  Thromb Res       Date:  2007-11-28       Impact factor: 3.944

9.  Chemoembolization of intermediate stage hepatocellular carcinomas: results from a Nordic tertiary liver cancer center.

Authors:  Kasper J Andersen; Henning Grønbaek; Gerda Elisabeth Villadsen; Anders Riegels Knudsen; Peter Ott; Hendrik Vildstrup; Dennis Tønner Nielsen; Arindam Bharadwaz
Journal:  Indian J Gastroenterol       Date:  2013-12-04

Review 10.  Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies.

Authors:  Suzanne van Meer; Robert A de Man; Peter D Siersema; Karel J van Erpecum
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.